Background: The aim of this study was to validate the Caregiver Reaction Assessment (CRA) among caregivers of community-dwelling advanced cancer patients in Japan. Methods: A cross-sectional questionnaire was administered to advanced cancer patients and their caregivers who were cared for at day hospices and home palliative care services. We translated the CRA into Japanese, and then verified factor validity, reliability, construct validity, concurrent validity, and known groups’ validity. To address construct and concurrent validity, we calculated Pearson’s correlation coefficient between the Japanese version of the CRA and the Burden Index of Caregivers (BIC). To address known groups’ validity, we used the t test or analysis of variance (ANOVA). Results: A total of 57 caregivers participated in the study. Five factors were extracted (‘‘impact on schedule,’’ ‘‘caregiver’s self-esteem,’’ ‘‘lack of family support,’’ ‘‘impact on health,’’ and ‘‘impact on finances’’) and reliability was good. Construct and concurrent validity among the subscales of the BIC were good. Regarding known groups validity, the subscale score of ‘‘impact on schedule’’ for the groups that cared 6 hours or more per day was higher than the other group (P = .04). Conclusion: The CRA-J is valid and reliable. This scale is useful for caregivers of cancer patients in Japan.
Background: The aims of this study were to clarify (1) the quality of life (QOL) of community-dwelling patients with advanced cancer and their caregivers in home palliative care and day hospice settings, (2) the need for day hospice of home palliative care patients and caregivers, and (3) the satisfaction with day hospice by day hospice patients and caregivers. Methods: A cross-sectional questionnaire was administered to patients with advanced cancer and their caregivers who were cared for at day hospice and home palliative care. We measured the health-related quality of life using the SF-8, the need for day hospice of home palliative care patients and caregivers, and the satisfaction with day hospice by day hospice patients and caregivers. Results: A total of 57 pairs of patients and caregivers participated in the study (day hospice, n = 23; home palliative care, n = 34). The physical and mental aspects of the patient QOL were significantly lower than national standard value. However, although physical aspect of caregivers QOL was significantly lower than national standard value, mental aspect of caregiver's QOL was not lower than national standard value. Forty-four percent of home palliative care patients and 67% of home palliative care caregivers preferred day hospice. The needs of patients and caregivers were wide ranging including medical treatment, distraction, information provision, and respite. Overall, the Japanese day hospice was evaluated highly. Conclusion: This is the first study of day hospice in Japan. Although there are several day hospices in Japan, the initiation of day hospice would probably be successful. The dissemination of day hospice is an important issue for patients with advanced cancer and their caregivers in Japan.
1 January 1999 in Archives of Histology and Cytology
Background: Cerebral ischemia causes a strong inflammatory response. Neumentix is a dietary supplement containing 14.9% rosmarinic acid and 29.9% total phenolic content, which has been proved to be beneficial against inflammatory response. Therefore, Neumentix’s effect on anti-inflammatory and blood brain barrier (BBB) disruption in transient middle cerebral artery occlusion (tMCAO) model mice is investigated in this study. Methods: After the pretreatment of vehicle or Neumentix 134 mg/kg/d, intraperitoneal injection (i.p.) (containing rosmarinic acid 20 mg/kg/d) for 14 days, mice were subjected to tMCAO for 60 min and kept receiving vehicle or Neumentix daily 5 days afterward. Results: Neumentix treatment ameliorated neurobehavioral impairment in the corner test (5d after tMCAO, **P<0.01), reduced infarct volume (#P<0.05), suppressed expression of ionized calciumbinding adapter molecule-1 (Iba-1), tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) (###P<0.001), and improved the integrity of BBB (§P<0.05) at 5 days after tMCAO. Conclusios: The present study provided an evidence of Neumentix’s anti-inflammatory and neuroprotection effect against BBB disruption on experimental tMCAO model mice, suggesting that Neumentix could be a potential therapeutic agent for stroke.